Recent Updates — NTNX
Director Craig Conway notified the company on October 5, 2026, that he will not stand for re-election at the upcoming annual meeting. He will remain on the board until then and his departure is unrelated to any disagreements regarding operations or policies. Separately, former President and Chief Commercial Officer Tarkan Maner entered into a twelve-month Transition Advisory Services Agreement effective October 7, 2026. Under this arrangement, Maner serves as a senior advisor for $37,500 per month without severance or equity acceleration. Nutanix provides enterprise cloud computing software and infrastructure solutions.
Nutanix, Inc. announced that Tarkan Maner will step down as President and Chief Commercial Officer effective October 2, 2026. Oversight of sales, marketing, and customer experience functions will transition to CEO Rajiv Ramaswami. The company is discussing a potential senior advisor arrangement for Mr. Maner. Nutanix, Inc. operates in the technology industry, providing enterprise cloud computing and data management software solutions.
Nutanix reported financial results for the fourth quarter and fiscal year ended July 31, 2026. For Q4 FY26, revenue increased 16% to $757.1 million, with GAAP operating income of $70.0 million and free cash flow of $277.6 million. Full-year FY26 revenue grew 12% to $2.85 billion, while ARR rose 16% to $2.55 billion. The company provided Q1 FY27 revenue guidance of $755–$765 million and full-year FY27 revenue guidance of $3.180–$3.230 billion. Nutanix operates in the hybrid cloud infrastructure software industry.
Nutanix announced a plan to reduce its global workforce by approximately 5% to streamline organizational structure and improve operational efficiency. The company expects to substantially complete the reduction by October 2026, incurring aggregate pre-tax charges of $33 million to $43 million, primarily for severance and termination benefits. Nutanix operates in the enterprise software industry, providing cloud computing and data management solutions.